BNTC BENITEC BIOPHARMA INC

Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy

Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy

Investor webcast to be held on Monday November 3, 2025 at 8:00 am EST

HAYWARD, Calif., Nov. 02, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference (“ddRNAi”) platform, today announced that it will provide an update on the six treated patients from Cohort 1 of its Phase 1b/2a Clinical Study of BB-301 being investigated for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD).

Webcast details:

Date: November 3, 2025

Time: 8:00 am EST

To register for the webcast, please click

About Benitec Biopharma Inc.

Benitec Biopharma Inc. (“Benitec” or the “Company”) is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary “Silence and Replace” DNA-directed RNA interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). A comprehensive overview of the Company can be found on Benitec’s website at .

Investor Relations Contact:



Irina Koffler

LifeSci Advisors

Tel: (917) 734-7387



EN
03/11/2025

Underlying

BNTCBENITEC BIOPHARMA INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BENITEC BIOPHARMA INC

 PRESS RELEASE
Free
BNTC BENITEC BIOPHAR...

Benitec Biopharma Releases Second Quarter 2026 Financial Results and P...

Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update -The first 4 Patients enrolled into Cohort 1 of the BB-301 Phase 1b/2a treatment study have completed the 12-month statistical follow-up period, and all 4 Completers were formal Responders to BB-301 at the 12-month follow-up timepoint demonstrating durable response to BB-301- -Patient 1 of Cohort 1 completed the 24-month follow-up timepoint, and at the 24-month post-treatment timepoint Patient 1 continued to experience the disease-modifying effects of BB-301, with deepening improvements in post...

February 12, 2026 1 EN
 PRESS RELEASE
Free
BNTC BENITEC BIOPHAR...

Benitec Biopharma Provides Positive Long-Term Clinical Study Results f...

Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response • Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at month-24 post-treatment Patient 1 continued to demonstrate the powerful disease-modifying effects of BB-301, with deepening improvements in post-swallow residue and total dysphagic symptom burden as compared to the 12-month follow-up timepoint • Patient 4 of Cohort 1 continued to experience strong response to BB-301 at the 12-month follo...

January 11, 2026 1 EN
 PRESS RELEASE
Free
BNTC BENITEC BIOPHAR...

Benitec Biopharma Releases First Quarter 2026 Financial Results and Pr...

Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update –Fast Track Designation was granted for BB-301 following U.S. Food and Drug Administration (FDA) review of positive interim clinical study results and proprietary Responder Analysis planned for use in pivotal study for BB-301– –Positive interim clinical study results from the Phase 1b/2a trial of BB-301, showed a 100% responder rate, with all six patients in Cohort 1 meeting the formal statistical criteria for response to BB-301– –First patient of Cohort 2 successfully treated with BB-301 in Q4...

November 14, 2025 1 EN
 PRESS RELEASE
Free
BNTC BENITEC BIOPHAR...

Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock ...

Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering HAYWARD, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA- directed RNA interference (“ddRNAi”) “Silence and Replace” platform, today announced the pricing of its underwritten public offering of 5,930,000 shares of its common stock and a concurrent registered direct offering of 1,481,481 shares of its common stock with long-ter...

November 6, 2025 1 EN
 PRESS RELEASE
Free
BNTC BENITEC BIOPHAR...

Benitec Biopharma Inc. Announces Proposed Public Offering

Benitec Biopharma Inc. Announces Proposed Public Offering HAYWARD, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA- directed RNA interference (“ddRNAi”) “Silence and Replace” platform, today announced that it has commenced an underwritten public offering of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and intends to conduct a concurrent registered direct offering of ...

November 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch